Migraine Patient Analyzer

Use the dropdown menus to select the appropriate information for your patient, then
click Analyze to see whether he or she is a candidate for migraine prevention therapy.

The TOPAMAX® Migraine Patient Analyzer helps to assess patient appropriateness for migraine prevention therapy based on AAN, AAFP, and ACP guidelines.^2,3*

* Adapted from the U.S. Headache Consortium guidelines for the management of migraines. Members include the American Academy of Neurology, the American Academy of Family Physicians, and the American College of Physicians-American Society of Internal Medicine.

Attention TOPAMAX patients and medical professionals

Dispensing errors have been reported between TOPAMAX^® (topiramate) Tablets and TOPROL-XL^® (metoprolol succinate) extended-release Tablets.

Please be sure to check your tablets to ensure you are taking the right medicine.

*TOPROL-XL is a registered trademark of the AstraZeneca group of companies.

TOPAMAX Tablets and TOPAMAX Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX in the acute treatment of migraine headache has not been studied.

TOPAMAX is contraindicated in patients with a history of hypersensitivity to any component of this product.

IMPORTANT SAFETY INFORMATION
TOPAMAX has been associated with serious adverse events, including:

Hyperchloremic, non-anion gap metabolic acidosis - lowering of bicarbonate levels in the blood. Measurement of baseline and periodic serum bicarbonate is recommended.
Acute myopia and secondary angle-closure glaucoma - patients should be cautioned to seek medical attention if they experience blurred vision or ocular pain.
Oligohidrosis and hyperthermia - decreased sweating and increased body temperature, especially in hot weather. The majority of reports have been in children.
Cognitive/psychiatric side effects including cognitive dysfunction, psychiatric/behavioral disturbances, including suicidal thoughts or behavior, and somnolence and fatigue.

Most common adverse events associated with TOPAMAX 100 mg vs placebo were: paresthesia, 51% vs 6%; anorexia,* 15% vs 6%; fatigue, 15% vs 11%; nausea, 13% vs 8%; diarrhea, 11% vs 4%; weight decrease, 9% vs 1%; taste alteration, 8% vs 1%.

The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX.

Patients should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation.

*Anorexia is defined as loss of appetite

Please see full U.S. Prescribing Information

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2008. All rights reserved. Your use of the information on this site is subject to our Legal Notice. Please see our Privacy Policy. This site is published by Ortho-McNeil Neurologics®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents. The TOPAMAX360.com, RAZADYNEER360.com, TOPAMAXEPILEPSY360.com, and AXERT360.com sites are directly affiliated with OMN360.com and the same terms of use apply across all sites.

This information is intended for the use of our customers, patients and healthcare professionals in the United States and Puerto Rico only. Ortho-McNeil Neurologics®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States and Puerto Rico.

Capitalized product names are trademarks of Ortho-McNeil-Janssen Pharmaceuticals, Inc.